Aditya Iyer

Aditya Iyer is the co-founder and CEO of Allos AI, an Oxford-based company applying causal AI to the reformulation of complex generic medicines. Born and raised in India, Iyer attended Bishop Cotton Boys’ School in Bengaluru before pursuing an undergraduate degree in Physics and Mathematics at the Hong Kong University of Science and Technology, where he specialised in International Research Enrichment. His academic path took him to CERN and McGill University before a DPhil in Quantum Information Theory at the University of Oxford, where he graduated in 2022.

At Oxford, Iyer became one of the early researchers in the field of quantum information theory, building transnational collaborations in theoretical physics before pivoting to health technology. He co-founded Allos in 2022 alongside the Entrepreneur First accelerator’s Polaris Fellow programme, applying his background in computational modelling to a problem in pharmaceutical development that he saw as structurally underserved: the difficulty of improving existing medicines after regulatory approval. His insight was that the pharmaceutical industry had concentrated AI investment on discovering new molecules, while the near-term opportunity — making existing specialty drugs more tolerable, bioavailable, and adherent for patients with chronic conditions — remained largely unaddressed.

Allos AI’s causal AI platform models how formulation, dosing, delivery method, and patient biology interact to drive clinical outcomes, grounding its analyses in real-world evidence from health records. The platform’s ‘glass-box’ architecture makes every recommendation interpretable and auditable — a design choice that reflects Iyer’s scientific background in systems that require transparency for validation. The company’s initial focus is on hard-to-genericise small-molecule drugs in chronic disease, where the specialty generics market is projected to grow from $77 billion in 2023 to $275 billion by 2032.

Allos AI raised £4 million in seed funding in January 2026, led by Oxford Science Enterprises, with participation from Habico Invest — the family office of Danish pharmaceutical group Orifarm — and Berkeley SKYDECK. Iyer has described the long-term ambition as building a platform that makes drug reformulation intentional, evidence-driven, and repeatable, fundamentally changing how complex drugs are developed, maintained, and experienced by patients.